Patent · US Expired

HEXIM1 as a suppressor of HIV replication and cardiac hypertrophy

US7132454B2 · kind B2 · utility

0Cited by

0References

6Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Qiang Zhou · Beijing, CN
Jasper Yik · Elk Grove, US
Ruichuan Chen · Stuttgart, DE

Key dates

Filing date	Aug 27, 2004
Grant date	Nov 7, 2006
Priority date	—
Expiry date	Jan 14, 2025

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K31/225
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.